<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Viking Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/viking-therapeutics-inc</link>
<description>Latest news and press releases for Viking Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/viking-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d35078dffbe2df120838.webp</url>
<title>Viking Therapeutics Inc</title>
<link>https://6ix.com/company/viking-therapeutics-inc</link>
</image>
<item>
<title>Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments.</description>
</item>
<item>
<title>Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-to-report-financial-results-for-first-quarter-2026-on-april-29-2026</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-to-report-financial-results-for-first-quarter-2026-on-april-29-2026</guid>
<pubDate>Wed, 22 Apr 2026 20:35:00 GMT</pubDate>
<description>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026.</description>
</item>
<item>
<title>Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-2-trial-of-vk2735</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-2-trial-of-vk2735</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc.</description>
</item>
<item>
<title>Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-fourth-quarter-210500309</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-fourth-quarter-210500309</guid>
<pubDate>Wed, 11 Feb 2026 21:05:00 GMT</pubDate>
<description>Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided an update on its clinical pipeline and other corporate developments.</description>
</item>
<item>
<title>Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-report-financial-results-210500634</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-report-financial-results-210500634</guid>
<pubDate>Wed, 04 Feb 2026 21:05:00 GMT</pubDate>
<description>Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026.</description>
</item>
<item>
<title>Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-publication-results-phase-2-venture-trial-dual-glp-1</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-publication-results-phase-2-venture-trial-dual-glp-1</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated</description>
</item>
<item>
<title>Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-completion-enrollment-maintenance-dosing-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-completion-enrollment-maintenance-dosing-clinical-trial</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss</description>
</item>
<item>
<title>Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-appointment-neil-aubuchon-chief-commercial-officer-2026</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-appointment-neil-aubuchon-chief-commercial-officer-2026</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing ExpertiseSAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking</description>
</item>
<item>
<title>Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference-2025</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-completion-enrollment-phase-3-vanquish-1-trial-vk2735</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-completion-enrollment-phase-3-vanquish-1-trial-vk2735</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest</description>
</item>
<item>
<title>Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-highlights-clinical-data-vk2735-obesity-program-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-highlights-clinical-data-vk2735-obesity-program-presentation</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO,</description>
</item>
<item>
<title>Viking Therapeutics to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-participate-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-participate-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the</description>
</item>
<item>
<title>Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-highlight-clinical-data-vk2735-obesity-program-presentations</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-highlight-clinical-data-vk2735-obesity-program-presentations</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO,</description>
</item>
<item>
<title>Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule VK2735 Phase 1 Maintenance</description>
</item>
<item>
<title>Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-initiation-vk2735-maintenance-dosing-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-initiation-vk2735-maintenance-dosing-clinical-trial</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be</description>
</item>
<item>
<title>Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-report-financial-results-third-quarter-2025-october-22-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-report-financial-results-third-quarter-2025-october-22-2025-2025</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking")</description>
</item>
<item>
<title>Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-positive-top-line-results-phase-2-venture-oral-dosing</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-announces-positive-top-line-results-phase-2-venture-oral-dosing</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to</description>
</item>
<item>
<title>Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
<description>Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial</description>
</item>
<item>
<title>Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025</title>
<link>https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-report-financial-results-second-quarter-2025-july-23-2025-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/viking-therapeutics-inc/news/viking-therapeutics-report-financial-results-second-quarter-2025-july-23-2025-2025-07</guid>
<pubDate>Wed, 16 Jul 2025 04:00:00 GMT</pubDate>
<description>Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking")</description>
</item>
</channel>
</rss>